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Sharing biotechnology with developing countries 
Start document for the symposium ‘Reconsidering Intellectual Property 
Policies (IPP) in public research’ 
 
Innovators often have to obtain scores of licenses before they can introduce their biotechnology product 
destined for poor farmers. The process costs a lot of time and money and does not guarantee success. In 
this way Intellectual Property Rights can block innovation in developing countries. The question for 
public research institutes is how they can prevent their intellectual property policy from hampering 
innovation in poor countries. The most promising strategies so far are ‘humanitarian licenses’ and ‘open 
source biotechnology’.  
 
By 1995, the Papaya Ringspot Virus (PRSV) had almost completely devastated the papaya industry in 
Hawaii. Thus there was an enormous need to introduce a disease-resistant papaya. The transgenic papaya 
developed by Cornell University in New York and Hawaii University had already shown excellent 
resistance in field trials, so the Papaya Administrative Committee (PAC) in Hawaii asked the American 
law firm Nixon Peabody to analyze the patent landscape, and negotiate licenses. At least ten licenses 
seemed to be needed, and the law firm encountered serious problems, but eventually the negotiations 
succeeded. Nixon Peabody and PAC were able to explain that the true beneficiaries were small papaya 
growers, and where sympathy for the growers was not sufficient, the United States Department of 
Agriculture (that created PAC) was helpful. As the USDA is an important regulatory agency, the licensors 
wanted to remain in the USDA’s good books so as to avoid jeopardising approvals for their own projects. 
All license agreements were completed by April 1998 and distribution of transgenic papaya seeds started 
in May 1998.  
Access becomes more difficult 
This case, extensively described in the IP Handbook of Best Practices 
(www.iphandbook.org – free access), demonstrates how difficult it has become 
to introduce a ‘small’ crop developed using modern biotechnology. But in this 
‘best practice’ at least, the negotiators succeeded. This was due to a number of 
factors: The Papaya Administrative Committee had enough money to pay a 
vested law firm, they received assistance from the influential USDA, and this 
papaya, developed in 1992, has fewer IPR’s than more recently developed 
transgenic varieties. In many other cases -rarely described in the literature - the 
negotiators did not succeed, or didn’t even start due to lack of money, legal 
expertise and time.   ‘Genetic information’ 
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As biotechnology becomes more complex, the number of IPR’s - and the risks of infringing them - 
increases. A cursory search of plant-related utility patents shows that patents filed under the United States 
Patent and Trademark Office (USPT) plant classification have increased steadily from 5 in 1981 to 777 in 
2006. About 45 patents and 6 material transfer agreements alone are associated with the famous vitamin A 
enriched Golden Rice. These patents are owned by approximately 30 companies and public institutions. 
Another example is the International Vaccine Institute in Seoul, devoted to bringing vaccines to the poor. 
It makes use of at least six distinct technology fields for the plant-derived vaccines they produce: 
engineering of antigens, antigen production and accumulation in plants, genetic transformation of plants, 
selectable marker systems (for the identification of plant cells that have successfully taken up the DNA), 
transcription regulatory elements (to ensure that the introduced genes are expressed in plants), sub-cellular 
targeting systems and bioprocess engineering for extraction and processing. All these areas are protected 
by scores of patents, confidential information agreements, and material transfer agreements.  
Access to IPR is not only a problem for transgenic crops. Conventional plant breeders are also 
increasingly making use of molecular technologies. Both these (enabling) technologies and the databases 
with (genomic) information are often protected.  
Two problems for the creators of products  
The increasingly complex patent landscape has led to two major problems for the creators of products for 
neglected markets. The first is the expensive process of analyzing the IPR landscape: which patents and 
other agreements do they need licenses for, and what are the chances of obtaining them? In many cases, 
searching for a biotechnology patent has become an inexplicably frustrating process. There is no 
streamlined, universal approach for searching for patents filed at the various patent offices. The three main 
repositories of English language filings – the European Patent Office (EPO), the US Patent and Trademark 
Office (USPTO) and the World Trade Intellectual Property Organisation’s Patent Cooperation Treaty – 
offer databases with online search tools that all work differently, even displaying different results. To 
make it worse, each patent of interest must be downloaded and printed one page at a time – even though it 
may be 100 pages long, and although patents and patent applications are disclosed, license agreements are 
often not. As researchers from the University of Tennessee conclude in Nature Biotechnology of 
November 2007: ‘Add to the mix defensive patenting, a complex classification system and a lack of 
information available on the license status of certain technologies, and it becomes difficult to know what 
privately developed technologies are available for use by researchers.’  
An even more serious problem is obtaining all licenses free, or for a price that the innovator can afford. In 
the case of the Hawaiian papaya, Michael Goldman from Nixon Peabody describes the bottlenecks: ‘All 
licensors were sympathetic to the need to introduce a transgenic, disease-resistant papaya in Hawaii’, he 
writes. ‘However, each had its own strategic interest, which needed to be protected.’ Most public 
institutions did not, at that time, have an institutional policy of, or experience with, licensing out and were 
reluctant to proceed with setting a corporate-wide strategy based on a license for a very small crop. Some 
were concerned that the deal with the Papaya Administrative Committee would dictate the terms for future 
licenses on more important crops. In addition, when the licensors saw that large, well-known fruit packing 
companies were members of PAC, questions were usually raised as to who was being aided by the 
licensors. So PAC had to explain a lot about the papaya industry. What made the negotiations more 
difficult was that many of the individuals working on business development for the licensors were very 
busy, and did not have much time for such a small crop with its potentially small economic return.   
Dilemma for public institutes  
The universities and the National Agricultural Research Institutes are now confronted with a dilemma. 
Researchers – also in the South – have been increasingly stimulated to protect their knowledge. With a 
stricter patent policy, financers hope to recoup the investment in research, and stimulate private-public 
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cooperation and ‘valorisation’. For instance, the Netherlands Ministry of Education, Science and Culture 
wants to stimulate patents on universities with a new measure: researchers will receive a part of the return 
from their own patents for private use, in order to keep top quality scientists in the public sector. Also the 
private sector – increasingly collaborating with universities – tends to lean toward stronger Intellectual 
Property protection.   
However, public institutions also want to assist poor countries. 
The Wageningen University and Research Centre’s 2007-2010 
Strategic Plan states that they want to ‘both strengthen 
international cooperation in the field of research and education, 
and take a more serious look at the possible international 
applications of existing knowledge.’ So on the one side 
researchers have to protect their knowledge, and on the other 
they have to share their knowledge in support of development 
goals. This issue was recently put on the agenda by the 
Netherlands Minister of Development Cooperation, Bert 
Koenders, at the ‘Knowledge on the Move Conference’ in The 
Hague on 28 February. This ministry is a strong proponent of 
sharing knowledge. ‘In relation to developing countries, access 
to knowledge is more important than possession of knowledge’, 
Koenders stated. He would also ‘urge Dutch universities and 
research institutes to adopt institutional IP policies that take 
account not only of valorisation of knowledge and incentives for 
researchers, but also the importance of access to knowledge and 
freedom to operate for development purposes.’ The EU is also 
paying attention to this problem. A workshop at the 
International Rice Research Institute (IRRI) this year – 
sponsored by the EU – will address the issue that ‘formal 
intellectual property right protection may impede the transfer of 
advanced technologies from EU public research to developing countries’.  
 
Adapting the patent policy  
So there may be several reasons for public research institutes to reconsider their own intellectual property 
policy, but what can they do to prevent developmental goals from being hampered by this policy. In the 
United States, each of the top four public recipients of U.S. patents in 2004 states ‘public benefit’ as an 
explicit goal in its patent policy. For instance, the California Institute of Technology (135 patents) has 
formulated it thus: ‘(…) If there are innovations or discoveries that result in the filing of patent 
applications and the acquisition of patents, the Institute intends to serve the public interest by prudent and 
appropriate efforts to transfer the technology to those who will facilitate public use.’ And the 
Massachusetts Institute of Technology (132 patents) writes: ‘(…) It is in the context of public service that 
M.I.T. supports efforts directed toward bringing the fruits of M.I.T research to public use and benefit.’  
Such general policy statements are needed to adapt the usual Intellectual Property strategy in an institute, 
but they do not provide insight into the  management of a specific project. When a Dutch public-private 
consortium starts breeding a Phytophthora resistant potato, or when an international consortium starts 
sequencing the banana, how can these consortiums formulate an IP strategy that doesn’t hamper the 
development of crops for neglected markets? Out of the international debates in the past twenty years, two 
concrete strategies have emerged: Humanitarian Licences and Open Source Biotechnology. Neither option 
infringes current IPR law, have been practiced, and are being developed for biotechnology.  
 
Potato market in Peru (Photo: R. Hoekstra) 
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Humanitarian Licences 
Humanitarian Use Licences (HULs) have always 
been part of IPR law. Governments are even allowed 
to force HULs, when they think a specific patent 
blocks a public goal, but they seldom use this right. 
According to Wikipedia, Humanitarian Use 
Licences ‘set the conditions for the provision of 
access to innovations for people in need on a 
royalty-free basis or at lower costs.’   
Universities offer several examples of humanitarian 
IP management. In 1996, the Wageningen 
University has transferred a patent (on a molecular 
technology to modify cassava) to the Dutch 
company Avebe. However, the university has 
ensured that the cassava technology can be used royalty free for for food security goals and local use, but 
not for the world trade in starch. The Cornell University has transferred its ring-spot-virus-resistant papaya 
to Haiiti and Thailand. And the most cited example is Golden Rice. The inventors of the technology 
(University of Freiburg) licensed their invention related to golden rice to Greenovation, a biotech spinout 
company, owned by the inventors themselves. Greenovation then exclusively licensed its Golden-Rice-
related patents to AstraZeneca (now Syngenta). However, in the licensing arrangements, a humanitarian-
use clause was used to commit the inventors to donating their technology to the poor. The arrangement 
allows for the granting of licenses to any bona fide research organisation for the development of Golden 
Rice. The rice can be used royalty free and allows farmers to earn up to US $10,000 per year from its sale. 
Higher sales would require farmers to acquire a commercial license from Syngenta. Other companies 
holding Golden-Rice-related patents also agreed to the same arrangement.  
Multinationals have already shown willingness to segment markets - they facilitate access to some of their 
technologies in poor countries. Examples include not only Golden Rice, but also the successful 
commercialisation of the transgenic, insect-resistant hybrid eggplant and the transgenic, disease-resistant 
groundnut in India. Both are orphan crops, developed with royalty-free licensed technology from 
Monsanto. In the case of the groundnut story, an agreement was penned for non-exclusive licensing of the 
so-called Coat Protein (CP) technology. The licenses are free of royalties and upfront payments to public 
institutions planning to develop the varietal groundnut, but they include upfront payments and royalties for 
companies planning to develop hybrid groundnut cultivars.  
High transaction costs 
Companies can win greater esteem from the public by accepting humanitarian licenses and, in some cases 
they also appear to use humanitarian licenses to open up a new market, for example by including specific 
obligations in the license. Hence humanitarian licenses may also be favorable for the donator. However, 
humanitarian licenses alone will probably not provide a solution for the long term, because of the high 
transaction cost involved with the need to arrange so many different licenses for an individual project. The 
market is already responding to this problem. Several initiatives aim at supporting technology transfer and 
lowering transaction costs for the creators of poor farmers biotechnology products. For example, the 
International Service for the Acquisition of Agri-biotech Applications (ISAAA) and, more recently, the 
African Agricultural Technology Foundation (AATF) have both been established to provide a broker role 
between technology users and providers. The ISAAA -  financed by companies, foundations and 
governmental institutes -  has brokered several transfers, including the transfer of local varieties of potato 
from Monsanto to Mexico, as well as the transfers of ring-spot virus resistant papaya from Monsanto and 
the delayed-ripening papaya from Syngenta - both in Southeast Asia. However, neither the goodwill of the 
Genetic Research on cabbage in India      
(Photo: W. Vroom) 
 5 
multinationals, nor the mediation by such organizations can provide a structural solution. These broker 
organizations do indeed reduce the transaction costs for the creators of products aimed at poor farmers, but 
barely reduce the total transactions costs.  
Formats for humanitarian licenses  
Transaction costs may be reduced by services designed to help 
steer clients to information and access to patented technology, 
some of which are for free. For instance, PatentMonkey 
(www.patentmonkey.com) offers free database searching, only 
charging fees for more extensive services. There are several non-
profit organisations that specialise in helping underserved 
communities in the developing world. The Coalition for Patent 
Fairness (www.patentfairness.org) is an advocacy group 
working to reform innovation-stifling practices and address 
patent litigation issues.  
Public institutes could lower transaction costs by accepting a 
format for humanitarian licenses that could serve as a standard in 
all cases. Consortia of research institutes could develop a clause 
in the consortium agreement that automatically grants a 
humanitarian license to all users of a certain category in a similar 
manner as the ‘Golden Rice’ contract. Such a clause has been 
developed by the participants of the Generation Challenge 
Programme, a programme of the Consultative Group on 
International Agricultural Research (CGIAR). The partners in this programme collectively work to use 
genomic techniques to increase the accessibility of genebank collections and to improve crop productivity 
in drought-prone environments.  
 
Open source biotechnology 
Another solution may be open databanks and pools of biotechnologies made freely available for 
humanitarian use. Databanks could list technologies, identify the owners and provide information on the 
specific licensing terms for each listed technology, including type of license, field of use and the intended 
beneficiaries for the use of the technology. One of the organisations working on this is the Public-Sector 
Intellectual Property Resource for Agriculture (PIPRA), based in the US. This organisation, funded by the 
Rockefeller and McKnight Foundations, identifies and develops approaches for encouraging technology 
managers to adopt humanitarian licensing models, and helps its 
members (through 40 institutes in the North and the South) access 
new agricultural technologies. PIPRA analyzes the members’ IP 
policy (on request), gives IP management workshops and has 
recently released the ‘IP Handbook of best cases’. The initiative also 
involves the development of a database to pool the IP assets (patents 
and licenses) of the participants.  
The public plant biotechnology institute CAMBIA based in New Zealand (www.cambia.org) develops 
technology for its own open technology bank, named BIOS. The technology has been patented, but is free 
under the terms of the group’s ‘Biological Open Source Licence’. Anyone using the technology has to 
contribute the improvements they make to the core toolkit – a model similar to the general public license 
used in open-source software. The CAMBIA technology includes a version of the important GUS 
Indian farmer (Photo: W. Vroom) 
(Logo taken from website) 
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technology, called GUSPLUS, and Transbacter, which bypasses the 
established and heavily patented transformation process for transferring 
genes into plants.  
A second, more recent initiative (in an even newer branch of technology) is the open bank of the 
BioBricks Foundation (http://bbf.openwetware.org/). The BioBricks Foundation is a not-for-profit 
organization founded by ‘synthetic biologists’ from MIT, Harvard, and the University of California. This 
foundation encourages the ‘development and responsible use of technologies based on BioBrick™ 
standard DNA parts that encode basic biological functions’. Everyone is invited to use the free DNA 
sequences, and to collaborate in building this bank. To stimulate participation, the foundation organizes an 
annual competition for student teams, called the International Genetically Engineered Machine 
competition (Igem). Each university team is obliged to put the DNA parts they have used for the Igem 
competition into the open source.  
Are the public institutes really confronted with a dilemma? 
 
Studying these initiatives, a second question may emerge: are the public institutes really confronted with a 
dilemma? The American Association for the Advancement of Science (AAAS) in the United States 
anticipates that at least some types of humanitarian IP strategies will have little or no impact on licensing 
revenues for the technology creator. As Amanda Brewster from the AAAS put forward in the IP 
Handbook, ‘Whether that will be the case may depend on whether humanitarian licensing becomes 
commonly practiced and accepted.’ The same will probably be true for collaborating with open databanks. 
When biomedical scientists Harold Varmus, Patrick Brown and Michael Eisen put forward their idea of 
high quality, free PLoS journals in 2000 many scientists were skeptical, but since the start in 2003, an 
increasing number of leading scientists have started to publish in a PLoS journal. Now, a publication in a 
PLoS journal has almost the same impact-factor for a research group as a publication in Science or Nature.  
 
Literature  
Atkinson RC, Beachy RN, Conway G, et al (2003) Public Sector Collaboration for Agricultural IP Management, 
Science 301: 174-173 
Brewster, L. Hansen, S. Chapman, A. (2007) Facilitating Humanitarian Access to Pharmaceutical and Agricultural 
Innovation, Handbook of best practices, chapter 22. 
Louwaars, N. (Ed). 2005. Genetic Resource Policies and the Generation Challenge Programme. Mexico D.F.: 
Generation Challenge Programme 
Koenders, B. Knowledge, growth and distribution: strengthening the capacity of innovation systems, Speech at the 
Institute of Scoial Studies, The Hague, 28 February 2008  
Yancey. A & Stewart. Louwaars N. (2007) Are university researchers at risk for patent infringement? Nature 
Biotechnology Volume 25 number 11  
Goldman, M. (2007) The IP Management of the PRSV-Resistant Papayas Developed by Cornell University and the 
University of Hawaii and Commercialized in Hawaii, Handbook of best practices chapter no 17.27 
The World Bank (2006) Intellectual Property Rights: Designing regimes to support plant breeding in developing 
countries. Report no. 35517-GLB 
(Logo taken from website) 
